17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Exclusion Criteria

• •Less than 15% blasts in peripheral blood or bone marrow AND \< 30% blasts and promyelocytes in peripheral blood or bone marrow
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •At least 6 months
• •Hematopoietic
• •See Disease Characteristics
• •Hepatic
• •Bilirubin \< 1.5 times ULN (3 mg/dL for patients with Gilbert's syndrome)
• •ALT or AST \< 2 times ULN
• •No known hepatitis positivity
• •Renal
• •Creatinine \< 1.5 times ULN OR
• •Creatinine clearance \> 60 mL/min
• •Cardiovascular
• •No New York Heart Association class III or IV cardiac disease
• •Pulmonary
• •No severe debilitating pulmonary disease, including any of the following:
• •* Dyspnea at rest
• •* Significant shortness of breath
• •* Chronic obstructive pulmonary disease
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 1 month after study participation
• •No known HIV positivity
• •No psychological or social condition that would preclude study compliance
• •No addictive disorder that would preclude study compliance
• •No family problems that would preclude study compliance
• •No known allergy or sensitivity to soy or other excipient components of study drug
• •No other illness or condition that may affect safety of study treatment or evaluation of study endpoints
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •More than 2 weeks since prior interferon
• •No concurrent interferon
• •Chemotherapy
• •More than 2 weeks since prior cytarabine (4 weeks for doses \> 100 mg)
• •More than 6 weeks since prior busulfan
• •No concurrent cytarabine
• •No concurrent hydroxyurea during the second study treatment course and beyond
• •No concurrent anagrelide during the second study treatment course and beyond
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified
• •Other
• •More than 2 days since prior imatinib mesylate
• •More than 1 week since prior and no concurrent drugs that alter metabolism by cytochrome P450 3A4, including the following:
• •* Diltiazem
• •* Nifedipine
• •* Verapamil
• •* Fluconazole
• •* Itraconazole
• •* Ketoconazole
• •* Lovastatin
• •* Simvastatin
• •* Indinavir
• •* Nelfinavir
• •* Ritonavir
• •* Alprazolam
• •* Diazepam
• •* Midazolam
• •* Triazolam
• •* Phenobarbital
• •* Phenytoin
• •* Carbamazepine
• •* Azithromycin
• •* Clarithromycin
• •* Erythromycin
• •* Rifampin
• •* Rifamycin
• •* Astemizole
• •* Terfenidine
• •* Amiodarone
• •* Cimetidine
• •* Cisapride
• •* Cyclosporine
• •* Grapefruit juice
• •* Hypericum perforatum (St. John's wort)
• •* Warfarin
• •More than 4 weeks since prior investigational drugs and recovered
• •No concurrent imatinib mesylate